Ivan da Rocha Pitta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ivan da Rocha Pitta has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Marina Galdino da Rocha Pitta
Laboratório de Planejamento e Síntese de Fármacos, Núcleo de Pesquisa em Inovação Terapêutica Suely Galdino, Universidade Federal de Pernambuco, Recife, Brazil
6 shared publications - Douglas Carvalho Francisco Viana
Laboratory of Drug Design and Synthesis (LPSF), Nucleus of Research in Therapeutic Innovation (NUPIT‐SG), Center of Biosciences Federal University of Pernambuco Recife Brazil
2 shared publications - José Arion da Silva Moura
Laboratory of Drug Design and Synthesis (LPSF), Nucleus of Research in Therapeutic Innovation (NUPIT‐SG), Center of Biosciences Federal University of Pernambuco Recife Brazil
2 shared publications - Marcel Lucas Almeida
Laboratório de Desenvolvimento Galênico, Farmácia Universitária, Universidade Federal do Rio de Janeiro, UFRJ, Rio de Janeiro 21941-901, Brazil
2 shared publications - Tiago Rafael de Sousa Nunes
Laboratory of Design and Drug Synthesis (LPSF), Nucleus of Research in Therapeutical Innovation Suely Galdino (NUPIT SG), Biosciences Center, Federal University of Pernambuco, Recife, Brazil
2 shared publications A. L. B. P. Duarte
Universidade Federal de Pernambuco, Hospital das Clínicas, Serviço de Reumatologia para contato
1 shared publication
Latest Publications
- 1 April 2022
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 23 (5) , 441-457
New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
: The quinolinic ring, present in several molecules, possesses a great diversity of biological activities. Therefore, this ring is in the structural composition of several candidates of drugs in pre-clinical and clinical studies; thus, it is necessary to compile these results to facilitate the design of new drugs. For this reason, some of the activities of compounds are selected to examine in this re-view, such as antimalarial, antimicrobial, anticancer, anti-inflammatory, antidiabetic, anti-rheumatic, and antiviral activities. All publications of scientific articles chosen are dated between 2000 and 2020. In addition to presenting the structures of some natural and synthetic compounds with their activities, we have listed the clinical studies of phases III and IV on antimalarial drugs containing the quinoline nucleus and phase III clinical studies on hydroxychloroquine and chloroquine to assess their possible role in COVID-19. Finally, we have reviewed some of the mechanisms of action, as well as the side effects of some of the quinolinic derivatives.
- 1 April 2022
- Published by Bentham Science Publishers Ltd. in Current Drug Targets
- Vol. 23 (5) , 441-457
New Trends in Biological Activities and Clinical Studies of Quinolinic Analogues: A Review
: The quinolinic ring, present in several molecules, possesses a great diversity of biological activities. Therefore, this ring is in the structural composition of several candidates of drugs in pre-clinical and clinical studies; thus, it is necessary to compile these results to facilitate the design of new drugs. For this reason, some of the activities of compounds are selected to examine in this re-view, such as antimalarial, antimicrobial, anticancer, anti-inflammatory, antidiabetic, anti-rheumatic, and antiviral activities. All publications of scientific articles chosen are dated between 2000 and 2020. In addition to presenting the structures of some natural and synthetic compounds with their activities, we have listed the clinical studies of phases III and IV on antimalarial drugs containing the quinoline nucleus and phase III clinical studies on hydroxychloroquine and chloroquine to assess their possible role in COVID-19. Finally, we have reviewed some of the mechanisms of action, as well as the side effects of some of the quinolinic derivatives.
- 17 November 2021
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 31 (1) , 108-119
Synthesis and biological activities of new phthalimide and thiazolidine derivatives
- 17 November 2021
- Published by Springer Nature in Medicinal Chemistry Research
- Vol. 31 (1) , 108-119
Synthesis and biological activities of new phthalimide and thiazolidine derivatives
- Open Access
- 21 August 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (11)
Análise do perfil de automedicação em tempos de COVID-19 no Brasil
Este manuscrito buscou a identificação do perfil brasileiro de automedicação na pandemia de COVID-19 e a reunião de informações sociodemográficas relacionadas ao uso da automedicação. Para tanto, foi investigado o conceito que os participantes depreendem sobre a automedicação, além de examinar qual o tipo de medicamento utilizado por quem se automedicou e seus efeitos colaterais. Foi realizada uma pesquisa no período de 03 de agosto a 30 de setembro de 2020. Os participantes deveriam apresentar uma idade mínima de 18 anos. As amostras estavam centradas em quem residia no Brasil. A pesquisa incluiu pessoas da população em geral. A coleta de dados se deu através de um questionário online, pois no referido período, as entrevistas presenciais deveriam ser evitadas devido ao contínuo lockdown. Coletaram-se dados de 1000 participantes para esta pesquisa. Os medicamentos que prevaleceram são da classe das vitaminas e, em segundo lugar, a Ivermectina. Destacou-se a indicação de automedicação por familiares. Os maiores índices de efeitos colaterais registrados foram cólicas intestinais e mal-estar. A prática da automedicação no Brasil mostrou-se preocupante no período de pandemia provocado pela COVID-19. Sendo assim, é importante que a população esteja atenta e seja criteriosa acerca das fontes de informações que discorrem sobre os medicamentos, evitando assim decisões precipitadas que podem ser mais prejudiciais.
- 21 August 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (11)
Open AccessAnálise do perfil de automedicação em tempos de COVID-19 no Brasil
Este manuscrito buscou a identificação do perfil brasileiro de automedicação na pandemia de COVID-19 e a reunião de informações sociodemográficas relacionadas ao uso da automedicação. Para tanto, foi investigado o conceito que os participantes depreendem sobre a automedicação, além de examinar qual o tipo de medicamento utilizado por quem se automedicou e seus efeitos colaterais. Foi realizada uma pesquisa no período de 03 de agosto a 30 de setembro de 2020. Os participantes deveriam apresentar uma idade mínima de 18 anos. As amostras estavam centradas em quem residia no Brasil. A pesquisa incluiu pessoas da população em geral. A coleta de dados se deu através de um questionário online, pois no referido período, as entrevistas presenciais deveriam ser evitadas devido ao contínuo lockdown. Coletaram-se dados de 1000 participantes para esta pesquisa. Os medicamentos que prevaleceram são da classe das vitaminas e, em segundo lugar, a Ivermectina. Destacou-se a indicação de automedicação por familiares. Os maiores índices de efeitos colaterais registrados foram cólicas intestinais e mal-estar. A prática da automedicação no Brasil mostrou-se preocupante no período de pandemia provocado pela COVID-19. Sendo assim, é importante que a população esteja atenta e seja criteriosa acerca das fontes de informações que discorrem sobre os medicamentos, evitando assim decisões precipitadas que podem ser mais prejudiciais.
- 27 July 2020
- Published by Bentham Science Publishers Ltd. in Current Organic Synthesis
- Vol. 17 (4) , 252-270
Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide
Phthalimide derivatives have been presenting several promising biological activities in the literature, such as anti-inflammatory, analgesic, antitumor, antimicrobial and anticonvulsant. The most well-known and studied phthalimide derivative (isoindoline-1,3-dione) is thalidomide: this compound initially presented important sedative effects, but it is now known that thalidomide has effectiveness against a wide variety of diseases, including inflammation and cancer. This review approaches some of the recent and efficient chemical synthesis pathways to obtain phthalimide analogues and also presents a summary of the main biological activities of these derivatives found in the literature. Therefore, this review describes the chemical and therapeutic aspects of phthalimide derivatives.
- 27 July 2020
- Published by Bentham Science Publishers Ltd. in Current Organic Synthesis
- Vol. 17 (4) , 252-270
Advances in Synthesis and Medicinal Applications of Compounds Derived from Phthalimide
Phthalimide derivatives have been presenting several promising biological activities in the literature, such as anti-inflammatory, analgesic, antitumor, antimicrobial and anticonvulsant. The most well-known and studied phthalimide derivative (isoindoline-1,3-dione) is thalidomide: this compound initially presented important sedative effects, but it is now known that thalidomide has effectiveness against a wide variety of diseases, including inflammation and cancer. This review approaches some of the recent and efficient chemical synthesis pathways to obtain phthalimide analogues and also presents a summary of the main biological activities of these derivatives found in the literature. Therefore, this review describes the chemical and therapeutic aspects of phthalimide derivatives.
- 30 January 2018
- Published by Springer Nature in International Journal of Obesity
- Vol. 42 (5) , 1062-1072
GQ-11: A new PPAR agonist improves obesity-induced metabolic alterations in LDLr−/− mice
Background Obesity and insulin resistance/diabetes are important risk factors for cardiovascular diseases and demand safe and efficacious therapeutics. Objective To assess the effects of a new thiazolidine compound—GQ-11—on obesity and insulin resistance induced by a diabetogenic diet in LDL receptor-deficient (LDLr−/−) mice. Methods Molecular docking simulations of GQ-11, PPARα and PPARγ structures were performed. Male C57BL/6J LDLr−/− mice fed a diabetogenic diet for 24 weeks were treated with vehicle, GQ-11 or pioglitazone or (20 mg/kg/day) for 28 days by oral gavage. Glucose tolerance test, insulin, HOMA-IR, adipokines (leptin, adiponectin) and the lipid profile were assessed after treatment. Adipose tissue was analysed by X-ray analysis and morphometry; gene and protein expression were evaluated by real-time PCR and western blot, respectively. Results GQ-11 showed partial agonism to PPARγ and PPARα. In vivo, treatment with GQ-11 ameliorated insulin sensitivity and did not modify subcutaneous adipose tissue and body weight gain. In addition, GQ-11 restored adipokine imbalance induced by a diabetogenic diet and enhanced Glut-4 expression in the adipose tissue. Improved insulin sensitivity was also associated with lower levels of MCP-1 and higher levels of IL-10. Furthermore, GQ-11 reduced triglycerides and VLDL cholesterol and increased HDL-cholesterol by upregulation of Apoa1 and Abca1 gene expression in the liver. Conclusion GQ-11 is a partial/dual PPARα/γ agonist that demonstrates anti-diabetic effects. Additionally, it improves the lipid profile and ameliorates chronic inflammation associated with obesity in atherosclerosis-prone mice.
- 30 January 2018
- Published by Springer Nature in International Journal of Obesity
- Vol. 42 (5) , 1062-1072
GQ-11: A new PPAR agonist improves obesity-induced metabolic alterations in LDLr−/− mice
Background Obesity and insulin resistance/diabetes are important risk factors for cardiovascular diseases and demand safe and efficacious therapeutics. Objective To assess the effects of a new thiazolidine compound—GQ-11—on obesity and insulin resistance induced by a diabetogenic diet in LDL receptor-deficient (LDLr−/−) mice. Methods Molecular docking simulations of GQ-11, PPARα and PPARγ structures were performed. Male C57BL/6J LDLr−/− mice fed a diabetogenic diet for 24 weeks were treated with vehicle, GQ-11 or pioglitazone or (20 mg/kg/day) for 28 days by oral gavage. Glucose tolerance test, insulin, HOMA-IR, adipokines (leptin, adiponectin) and the lipid profile were assessed after treatment. Adipose tissue was analysed by X-ray analysis and morphometry; gene and protein expression were evaluated by real-time PCR and western blot, respectively. Results GQ-11 showed partial agonism to PPARγ and PPARα. In vivo, treatment with GQ-11 ameliorated insulin sensitivity and did not modify subcutaneous adipose tissue and body weight gain. In addition, GQ-11 restored adipokine imbalance induced by a diabetogenic diet and enhanced Glut-4 expression in the adipose tissue. Improved insulin sensitivity was also associated with lower levels of MCP-1 and higher levels of IL-10. Furthermore, GQ-11 reduced triglycerides and VLDL cholesterol and increased HDL-cholesterol by upregulation of Apoa1 and Abca1 gene expression in the liver. Conclusion GQ-11 is a partial/dual PPARα/γ agonist that demonstrates anti-diabetic effects. Additionally, it improves the lipid profile and ameliorates chronic inflammation associated with obesity in atherosclerosis-prone mice.
- 1 January 2011
- Published by AIP Publishing in AIP Conference Proceedings
- p. 55-59
Evaluation of Photodynamic Antimicrobial Therapy (PACT) against Trypomastigotes of Trypanosoma cruzi: In Vitro Study
Policies to combat Chagas disease presents a considerable degree of negligence and is classified at level III by TDR, where the focus of research is based on the improvement and wider dissemination of existing tools and strategies for combating them. The PACT is based on topical or systemic administration of a nontoxic dye sensitive to light, followed by low dose irradiation with visible light of wavelength appropriate. In the presence of oxygen found in the cells, the photosensitizer (FS) enabled may react with molecules in its vicinity by electron transfer or hydrogen, leading to production of free radicals (type I reaction) or by energy transfer to oxygen (type II reaction), leading to production of singlet oxygen. Both paths can lead to cell death and the destruction of diseased tissue. In this work, we verify the effectiveness of PACT associated with a semiconductor laser InGaAlP, a wavelength (λ) equal to 30 mW optical power, emitting red light in the visible spectrum, with a dose of in continuous mode, using methylene blue in five differents concentrations on the infective trypomastigote forms of Trypanosoma cruzi. To determine the viability of the parasites, one sample from each treatment group at each concentration was removed and analyzed in a hemocytometer, observing the decrease in the number of live parasites for the solution without treatment. The results demonstrated significant percentage of parasite lysis (up to 86% lethality), what can not be observed in the groups treated with laser or with the FS.- 1 January 2011
- Published by AIP Publishing in AIP Conference Proceedings
- p. 55-59
Evaluation of Photodynamic Antimicrobial Therapy (PACT) against Trypomastigotes of Trypanosoma cruzi: In Vitro Study
Policies to combat Chagas disease presents a considerable degree of negligence and is classified at level III by TDR, where the focus of research is based on the improvement and wider dissemination of existing tools and strategies for combating them. The PACT is based on topical or systemic administration of a nontoxic dye sensitive to light, followed by low dose irradiation with visible light of wavelength appropriate. In the presence of oxygen found in the cells, the photosensitizer (FS) enabled may react with molecules in its vicinity by electron transfer or hydrogen, leading to production of free radicals (type I reaction) or by energy transfer to oxygen (type II reaction), leading to production of singlet oxygen. Both paths can lead to cell death and the destruction of diseased tissue. In this work, we verify the effectiveness of PACT associated with a semiconductor laser InGaAlP, a wavelength (λ) equal to 30 mW optical power, emitting red light in the visible spectrum, with a dose of in continuous mode, using methylene blue in five differents concentrations on the infective trypomastigote forms of Trypanosoma cruzi. To determine the viability of the parasites, one sample from each treatment group at each concentration was removed and analyzed in a hemocytometer, observing the decrease in the number of live parasites for the solution without treatment. The results demonstrated significant percentage of parasite lysis (up to 86% lethality), what can not be observed in the groups treated with laser or with the FS.